Paper 31 - THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY

Author(s)

• 

  Robin L. Jones, BSc, MB BS, Royal Physician MRCP, MD

  Professor
  Medical Oncology, The Royal Marsden and Institute of Cancer Research
  London, England, United Kingdom

  Slides

Co-Author(s)

• VW

  Victoria Wang, MD, PhD

  Assistant Professor
  Division of Hematology/Oncology, UCSF
  San Francisco, California, United States
• MD

  Mark Doherty, MB, BCh, BAO, MSc, MRCPI (he/him/his)

  Consultant Medical Oncologist
  St. Vincent's UCD Cancer Centre
  Dublin, Dublin, Ireland
• AS

  Ana Sebio García, MD, PhD

  Medical Oncologist
  Hospital de la Santa Creu i Sant Pau, IR Sant Pau
  Barcelona, Catalonia, Spain
• 

  Silvia Stacchiotti, MD

  Medical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• 

  Breelyn A. Wilky, MD (she/her/hers)

  Associate Professor
  University of Colorado School of Medicine
  Aurora, Colorado, United States
• 

  Jean-Yves Blay, MD, PhD

  Président UNICANCER, Director of Public Policy ESMO, General Director
  Centre Léon Bérard
  Lyon, Rhone-Alpes, France
• 

  Peter Reichardt, MD, PhD (he/him/his)

  Head
  Oncology and Palliative Care / Sarcoma Center Professor of Oncology, Medical School Berlin Chairman of the German Sarcoma Foundation, Helios Klinikum Berlin-Buch
  Berlin, Berlin, Germany
• 

  Javier Martín-Broto, MD, PhD

  Medical Oncologist
  Fundación Jiménez Díaz University Hospital
  Madrid, Madrid, Spain
• 

  Dale R. Shepard, MD, PhD

  Director, Taussig Early Cancer Therapeutics and Co-Director Cleveland Clinic Sarcoma Programs
  Cleveland Clinic
  Cleveland, Ohio, United States
• 

  Claudia M. Valverde Morales, MD (she/her/hers)

  Vall d’Hebron University Hospital
  Barcelona, Catalonia, Spain
• 

  Elizabeth J. Davis, MD

  Associate Professor of Medicine
  Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee, United States
• Jd

  Jacco J. de Haan, MD, PhD

  University Medical Center Groningen
  Groningen, Groningen, Netherlands
• 

  Andrew Brohl, MD (he/him/his)

  Associate Member
  H. Lee Moffitt Cancer Center and Research Institute
  Tampa, Florida, United States
• 

  Gloria Marquina, MD, PhD (she/her/hers)

  Department of Medical Oncology, Hospital Clínico San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), Instituto de Investigación Sanitaria (IdISSC), EURACAN Referral Centre, Madrid, Spain
  Department of Medical Oncology, Hospital Clinico San Carlos, School of Medicine, UCM, IdissC, EURACAN referral centre
  Madrid, Madrid, Spain
• 

  Anthony P. Conley, MD

  Associate Professor
  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Lara E. Davis, MD

  Sarcoma Program Director
  Knight Cancer Institute, Oregon Health & Science University
  Portland, Oregon, United States
• AL

  Axel Le Cesne, MD

  Head
  International Department, Gustave Roussy Institute
  Villejuif, Ile-de-France, France
• CM

  Christian F. Meyer, MD, PhD (he/him/his)

  Clinical Associate/Assistant Professor
  Johns Hopkins Hospital
  Baltimore, Maryland, United States

Co-Author(s)

• 

  Mia Weiss, MD

  Assistant Professor of Medicine
  Washington University
  St Louis, Missouri, United States

Co-Author(s)

• SA

  Sandra Aliberti, MD

  Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS
  Turin, Piemonte, Italy
• 

  Ciara Kelly, MBBCh, BAO

  Assistant Attending Physician
  Sarcoma Medical Oncology Service, Memorial Sloan Kettering
  New York, New York, United States
• 

  Seth M. Pollack, MD

  Sarcoma Program Director
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois, United States
• 

  Sandra Strauss, FRCP, PhD (he/him/his)

  Professor of Medical and TYA Oncology
  University College London Cancer Institute
  London, England, United Kingdom
• JG

  Josep Garcia, PhD

  Inhibrx Biosciences, Inc.
  La Jolla, California, United States
• 

  Brianne O'Neill, PhD (she/her/hers)

  Sr. Director, Clinical Science
  Inhibrx Biosciences, Inc.
  La Jolla, California, United States
• EB

  Erin Babcock, PhD

  Inhibrx Biosciences, Inc.
  La Jolla, California, United States
• YL

  Yang Li, MA

  Inhibrx Biosciences, Inc.
  La Jolla, California, United States

Co-Author(s)

• 

  James Kalabus, PhD (he/him/his)

  Sr. Director, Translational & Clinical Pharmacology
  Inhibrx Biosciences, Inc
  La Jolla, California, United States

Co-Author(s)

• 

  Sant P. Chawla, MD

  Director
  Sarcoma Oncology Center
  Santa Monica, California, United States
• 

  Hans Gelderblom, MD, PhD

  Professor medical oncology
  Leiden University Medical Center
  Leiden, Zuid-Holland, Netherlands